论文部分内容阅读
慢性乙型肝炎病毒(HBV)感染是引起肝硬化和肝细胞癌的最主要原因。我国慢性乙肝病毒携带者已达1.2亿左右,这是一个内涵相当复杂的群体,可以由肝组织正常至肝硬化的不同病变谱[1],因此,对慢性乙型肝炎病毒携带者的治疗逐渐被重视。我们选择慢性乙型肝炎病毒携带者行肝组织免疫组
Chronic hepatitis B virus (HBV) infection is the leading cause of cirrhosis and hepatocellular carcinoma. Chronic hepatitis B virus carriers in China have reached about 120 million, which is a very complex connotation of the group, from normal to cirrhosis of the liver lesions of different spectrum [1], therefore, the treatment of chronic hepatitis B virus carriers gradually emphasized. We choose the chronic hepatitis B virus carrier liver transplantation group